Jiangsu Jibeier Pharmaceutical Co., Ltd.

SHSE:688566 Stock Report

Market Cap: CN¥4.4b

Jiangsu Jibeier Pharmaceutical Future Growth

Future criteria checks 4/6

Jiangsu Jibeier Pharmaceutical is forecast to grow earnings and revenue by 23.7% and 23.2% per annum respectively. EPS is expected to grow by 23.5% per annum. Return on equity is forecast to be 14.5% in 3 years.

Key information

23.7%

Earnings growth rate

23.5%

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth rate23.2%
Future return on equity14.5%
Analyst coverage

Low

Last updated02 Sep 2024

Recent future growth updates

No updates

Recent updates

Jiangsu Jibeier Pharmaceutical's (SHSE:688566) Solid Earnings May Rest On Weak Foundations

Nov 06
Jiangsu Jibeier Pharmaceutical's (SHSE:688566) Solid Earnings May Rest On Weak Foundations

Even With A 38% Surge, Cautious Investors Are Not Rewarding Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) Performance Completely

Oct 08
Even With A 38% Surge, Cautious Investors Are Not Rewarding Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) Performance Completely

Does Jiangsu Jibeier Pharmaceutical (SHSE:688566) Deserve A Spot On Your Watchlist?

Oct 01
Does Jiangsu Jibeier Pharmaceutical (SHSE:688566) Deserve A Spot On Your Watchlist?

Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) Shares Lagging The Market But So Is The Business

Jul 30
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) Shares Lagging The Market But So Is The Business

Impressive Earnings May Not Tell The Whole Story For Jiangsu Jibeier Pharmaceutical (SHSE:688566)

May 02
Impressive Earnings May Not Tell The Whole Story For Jiangsu Jibeier Pharmaceutical (SHSE:688566)

Earnings and Revenue Growth Forecasts

SHSE:688566 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,549414N/A3912
12/31/20251,277335N/A3362
12/31/20241,051272N/A4842
9/30/20248872394234N/A
6/30/2024876245-77181N/A
3/31/2024890234-148139N/A
12/31/2023861219-198160N/A
9/30/2023845230-211143N/A
6/30/2023816209-187194N/A
3/31/2023681164-104236N/A
12/31/2022655155-142151N/A
9/30/2022569118-84155N/A
6/30/2022516101-4161N/A
3/31/20225281178149N/A
12/31/202151011567151N/A
9/30/202153012787130N/A
6/30/202157414094130N/A
3/31/202157013293114N/A
12/31/202056613094117N/A
9/30/2020543118112142N/A
6/30/202053011085117N/A
3/31/202053111480117N/A
12/31/201954311385115N/A
12/31/2018485979098N/A
12/31/201745278N/A112N/A
12/31/201644477N/A39N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688566's forecast earnings growth (23.7% per year) is above the savings rate (2.8%).

Earnings vs Market: 688566's earnings (23.7% per year) are forecast to grow slower than the CN market (25.4% per year).

High Growth Earnings: 688566's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688566's revenue (23.2% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 688566's revenue (23.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688566's Return on Equity is forecast to be low in 3 years time (14.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:31
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Jibeier Pharmaceutical Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Song YangTianfeng Securities Brokerage Co., Ltd
Tielin ChenTopsperity Securities
Xinming ZhouTopsperity Securities